Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages  by Tanz, Rachid et al.
original research report
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com 31
Endometrial stromal sarcomas (ESS) are rare uterine neoplasms. Conventionally divided into high and low grade by histological aspect 
and mitotic activity, high-grade tumors are currently 
included in undifferentiated uterine sarcoma (and 
low-grade ESS is what is referred to as ESS cur-
rently). Surgery remains the cornerstone of treatment 
for localized stages and consists of an abdominal 
hysterectomy with bilateral salpingo-oopherectomy, 
however, the relapse rate remains high (18%-45%) 
and might be improved by adjuvant therapy not yet 
well defined. We conducted this study investigate the 
prognostic factors for relapse and to review the im-
pact of adjuvant therapy.
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BACKGROUND AND OBJECTIVES: Endometrial stromal sarcomas (Ess) are rare uterine neoplasms. surgery 
remains the cornerstone of treatment for early stages and consists of an abdominal hysterectomy with bilateral 
salpingo-oopherectomy. Despite appropriate surgical treatment, relapse rates are high (18% to 45%) and the 
value of adjuvant therapies is not clear.  We evaluated prognostic factors and the impact of adjuvant treatment 
on localized Ess (stages i and ii).
DESIGN AND SETTING: retrospective, case-control study conducted at the national institute of oncology in 
rabat, morocco over 10 years from 2000 to 2009.
PATIENTS AND METHODS: twenty-one cases of localized Ess were included in the analysis. 
RESULTS: standard surgery was performed in 71.4% of our patients. myometrial invasion was noted in 57.1% 
of cases. mitotic activity was considered high in five patients. adjuvant treatment was given to 52.3% of pa-
tients: endocrine therapy in five patients and radiotherapy in six. survival was significantly longer in the group 
of patients who underwent standard surgical treatment (P=.0007), in the absence of deep myometrial invasion 
(P=.0248) in cases with a low mitotic index (P<.0001) and in patients who received adjuvant therapy (hormone 
or radiotherapy) (P=.0048). in a multivariate analysis independent risk factors for monitoring were inadequate 
surgical treatment and absence of adjuvant treatment.
CONCLUSIONS: myometrial invasion and mitotic index appear to be important prognostic factors. the refer-
ence surgery is hysterectomy with bilateral salpingo-oopherectomy. Lymph node dissection does not appear to 
provide a benefit. finally adjuvant treatment may carry a significant survival benefit.
PATIENTS AND METHODS 
This was a retrospective case-control study involving 
cases of localized ESS (stages I and II) treated at the 
National Oncology Institute in Rabat, Morocco over 10 
years from 2000 to 2009. In this study patients with 
histologically confirmed low-grade ESS, stages I and II 
were included. High-grade tumors, and advanced stages 
were excluded. All our patients had a histological con-
firmation in the pathology department of the institute. 
The primary endpoint of this study was disease-free 
survival at 3 years; the probability of survival was calcu-
lated by the Kaplan and Meier method and multivariate 
Cox regression. SPSS version 17.0 was used for statisti-
cal tests. The difference was considered significant for P 
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Table 1. epidemiological characteristics of the 21 patients with 
endometrial stromal sarcomas.
Characteristics n %
Age
   Median (range) 50.0 (27-76)
   ≤60 years 15 71.4
   ≥60 years 6 28.6
Symptoms
   abnormal vaginal 
   bleeding 14 66.7
   Other 7 33.3
Diagnosis
   dilatation-
   curettage 7 33.3
   Biopsy 6 28.7
   Surgery 8 38.1
Stage
   i 12 57.1
   ii 9 42.9
Table 2. Treatment characteristics.
Characteristics n %
Surgery
   Standard 11 52.4
   Other 10 47.6
Lymph node 
dissection
   no 15 71.4
   Yes 6 28.6
   Sampling 2 9.5
   Systemic 4 19.0
Adjuvant treatment 11 52.3
   radiotherapy 6 28.6
   Hormones 5 23.8
values less than .05. The ethics committee of the mili-
tary hospital in Rabat approved this study. 
RESULTS
The 21 patients had a median age of 50 years (range, 
27-76 years). The reason for consultation was abnormal 
vaginal bleeding in 14 patients (66.7%), an abdominal 
mass in 3 patients, pelvic pain in 2 patients and 2 pa-
tients underwent emergency surgery for acute abdomen 
(Table 1). A standard surgery (abdominal hysterec-
tomy with bilateral salpingo-oopherectomy) was per-
formed in 71.4% of our patients (n=15). Three patients 
underwent hysterectomy alone (14.3%). A subtotal 
hysterectomy was performed in two cases and one pa-
tient refused surgery.
Sixteen (76.2%) did not undergo lymph node dissec-
tion. The dissection was negative in three patients and 
two (9.5%) had metastatic lymph nodes. Myometrial 
invasion was noted in 57.1% of cases, including five 
with superficial invasion and seven with deep invasion. 
Nine patients (42.8%) had no invasion.
Mitotic activity was considered low (less than 5/
high power field) in 6.2% (n=16) and high (above 5/ 
high power field) in five cases (23.8%) (Table 2). Eleven 
(52.3%) received adjuvant therapy (n=11), 5 endocrine 
therapy and 6 radiotherapy (Table 3). At a mean fol-
low up of 54.5 (13) months eight recurrences were 
Table 3. Pathologic characteristics.
Characteristics n %
Myometrial 
invasion
   no 9 42.8
   Yes 12 57.2
   low 5 23.8
   deep 7 23.8
Mitotic index
   low 9 42.9
   High 12 57.1
Nodes
   n0 3 14.3
   n+ 2 9.5
Hormonal 
receptors
   Positive 16 76.1
   negative 0 0
   unknown 5 23.8
observed (38.1%), four isolated local recurrences, three 
local and metastasic and one patient had relapse only in 
the lungs. Survival was significantly longer in the group 
of patients who underwent standard surgical treatment 
versus the rest (P=.0007), in the absence of deep myo-
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Figure 1. disease-free survival probability by type of surgery (a), mitotic index (B), myometrial invasion (C) and adjuvant treatment (d).
metrial invasion versus presence (P=.0248) in case of 
low versus high mitotic index (P<.0001) and in patients 
who received adjuvant therapy (hormone or radiother-
apy) versus the rest (P=.0048) (Figure 1). Age, tumor 
stage and lymph node dissection did not significantly 
influence survival (P=.482, 0.450 and 0.225 respec-
tively).
The factors found significant in univariate analysis 
were tested in the multivariate analysis. Independent 
risk factors were inadequate surgical treatment and ab-
sence of adjuvant treatment (Table 4). 
DISCUSSION
ESS are rare tumors, constituting approximately 10% 
of uterine sarcomas and only 0.2% of cancers of the 
uterus.1,2 Most reports in the literature are case reports 
or retrospective series about a small number of patients 
including other histological types of uterine sarcomas. 
Our series is, to our knowledge, one of the few studies 
focusing specifically on prognostic factors and adjuvant 
treatments in located ESS. Most (71.4%) of our pa-
tients were young (younger than 60) without a signifi-
cant impact of age on survival. Data are quite diverse in 
this regard. Denschlag et al3 and Kokawa et al4 found 
that young age was correlated with better survival.
A retrospective study of 800 cases reported better 
survival for the age group younger than 52 years, and 
included age as independent prognostic factor in mul-
tivariate analysis.5 These results should be taken with 
caution because these studies included advanced stages 
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Table 4. Multivariate analysis (Cox proportional hazards models).
Prognosis factors Hazard ratio 95% Confidence interval P
Surgery 9.05 8.54-11.65 .001
adjuvant treatment 3.34 3.04-6.10 .005
and were based on the old histological classification 
including high-grade ESS, which is currently consid-
ered among undifferentiated sarcomas. Our results are 
consistent with a recent report that focused only on 
localized stages and age had no significant influence on 
survival.6
Myometrial invasion and high mitotic index were 
factors of poor prognosis in our study although not 
found significant in multivariate analysis. These same 
factors were reported in the literature as predictors of 
relapse, mainly the presence of deep myometrial inva-
sion, which should be an indication for discussing ad-
juvant therapy.6,7 Hysterectomy with bilateral salpin-
go-oopherectomy is considered the standard surgical 
treatment for this cancer in our series and others.6 The 
absence of oophorectomy was a factor for poor prog-
nosis.
The problem of ovarian preservation remains un-
solved in young women, because most reports are con-
cordant about the possibility of conservative surgery 
in premenopausal women.5,8-11 This practice was not 
found in these series as affecting survival negatively; 
however, Li et al12 reported in their series of 53 patients 
a significantly increased risk of relapse in nine patients 
who had ovarian conservation for ESS compared with 
oopherectomy patients.
Pelvic and para-aortic lymphadenectomy has not 
provided evidence of a survival benefit its realization is 
not recommended in the guidelines.5,13,14 In our series 
there was no significant difference in survival between 
patients who had undergone lymph node dissection 
and the rest of the sample, nor for node negative or 
node positive patients in whom lymphadenectomy was 
performed.
Despite appropriate surgical treatment, relapse 
rates are high, increasing the tendency to offer adju-
vant therapy. Based on the demonstrated effectiveness 
of endocrine therapy: progesterone, castration, tamox-
ifen and aromatase inihibitors15,16 in metastatic ESS, 
several studies have demonstrated improved survival 
with adjuvant hormonal therapy.17,18 Adjuvant radio-
therapy improves local control but has a modest effect 
on survival.19, 20 A limitation of the study is the lack of 
comparison of the forms of adjuvant therapy. In our 
study survival benefit was seen with both hormonal 
and radiotherapy. This same observation was found in 
the series of Malouf et al6 and the authors concluded 
that hormonal therapy due to its safety can be an alter-
native to adjuvant radiotherapy.
Myometrial invasion and mitotic index appear to 
be important prognostic factors and should be taken 
into account when discussing adjuvant treatment of lo-
cated endometrial stromal sarcoma. Standard surgery 
is hysterectomy with bilateral salpingo-oopherectomy. 
Lymph node dissection does not seem to provide a 
benefit. Finally adjuvant treatment seems to bring 
some gain in survival and hormonal therapy appears 
attractive in this setting because of its safety compared 
to radiotherapy, but studies should be conducted to 
compare these two treatment modalities.
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